Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
PALO ALTO, Calif., June 10, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company's 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing the world's most urgent challenges.
Shield is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for CRC. The second leading cause of cancer-related deaths in the U.S., CRC has a 91 percent five-year survival rate if caught in early stages. Yet one out of three eligible adults in the U.S. (over 50 million people) do not complete the recommended screening in part because they find the available options—colonoscopy and stool tests—unpleasant or inconvenient. With Shield, individuals can be screened with a simple blood draw during a routine office visit, helping to detect more cancers early, when they are more treatable.
"With a simple blood draw, Shield provides a more convenient and pleasant screening option for the millions of people who delay their recommended screening for colorectal cancer," said AmirAli Talasaz, Guardant Health co-founder and co-CEO. "This latest honor for Shield recognizes the groundbreaking innovation created by our team at Guardant Health and the world-changing potential of the Shield blood test. By overcoming barriers with current screening methods, we can help increase the overall screening rate, find more cancers at an early stage, and give people more time free from cancer."
A panel of Fast Company editors and reporters selected the winners from a pool of more than 1,500 entries and judged applications based on their impact, sustainability, design, creativity, scalability, and ability to improve society. This year's awards are featured on fastcompany.com.
"The World Changing Ideas Awards have always been about showcasing the art of the possible," says Fast Company editor-in-chief Brendan Vaughan. "We're proud to recognize the organizations and leaders that are making meaningful progress on the biggest issues of our time."
The Shield blood test was also named to TIME's list of the best inventions of 2024 and selected as a Grand Award Winner in Popular Science's Best of What's New 2024 (Health category). Shield is also the first blood test that is FDA approved for primary screening to be included in The National Comprehensive Cancer Network (NCCN) colorectal cancer (CRC) screening guidelines.
Shield is FDA approved for primary non-invasive screening for colorectal cancer in average-risk individuals age 45 and older and can be ordered by any prescribing healthcare provider. For more information, visit www.ShieldCancerScreen.com.
About Shield
Shield is a non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Guardant Health Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610836481/en/
Contacts
Investor Contact: Zarak Khurshidinvestors@guardanthealth.com
Media Contact: Michael Weistpress@guardanthealth.com +1 317-371-0035
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Perpetua Resources Announces Upsizing of Previously Announced Bought Deal Public Offering of Common Shares
BOISE, Idaho, June 12, 2025 /CNW/ - Perpetua Resources Corp. (Nasdaq: PPTA) (TSX: PPTA) ("Perpetua Resources" or the "Company") announced today that as a result of excess demand, it has agreed with the syndicate of underwriters led by National Bank of Canada Financial Markets and BMO Capital Markets, on behalf of themselves and a syndicate of underwriters (the "Underwriters") to increase the size of its previously announced bought deal financing. Perpetua Resources will now issue 24,622,000 common shares, no par value, of the Company (the "Common Shares") at a price of US$13.20 per Common Share (the "Offering Price") for aggregate gross proceeds of approximately US$325 million (the "Offering"). National Bank of Canada Financial Markets and BMO Capital Markets are acting as joint lead bookrunning managers for the Offering. In connection with the Offering, Paulson & Co. Inc. has entered into an agreement to purchase US$100 million of Common Shares in a private placement (the "Private Placement") at the Offering Price. Perpetua Resources has also granted the Underwriters an option (the "Option") to purchase up to an additional 3,693,300 Common Shares representing up to 15% of the number of Common Shares to be sold pursuant to the Offering. The Underwriters have 30 days from the closing of the Offering to exercise the Option. In connection with the Offering, an underwriting agreement has been entered into by and among Perpetua Resources, National Bank of Canada Financial Markets and BMO Capital Markets as representatives of the several Underwriters (the "Underwriting Agreement"). In the event that the Option is exercised in full, the aggregate gross proceeds of the Offering will be approximately US$374 million. The Company intends to use the proceeds of the Offering and the Private Placement as part of a comprehensive financing package for the development of the Company's Stibnite Gold Project (the "Project") in conjunction with the previously announced application for up to US$2 billion in project financing submitted to the Export-Import Bank of the United States ("EXIM") in May 2025. The Company intends to designate the proceeds of the Offering and the Private Placement toward equity requirements for the EXIM debt financing, with any additional funds intended to support exploration activities, working capital and general corporate purposes. EXIM's due diligence on the Company's application is ongoing and is conditional upon successfully completing the due diligence and underwriting process. If the due diligence process is successful, the Company anticipates closing the debt financing in 2026. The Offering is expected to close on or about June 16, 2025. Closing of the Offering will be subject to a number of customary conditions to be included in the Underwriting Agreement. The Offering to the public in the United States is being made pursuant to the Company's effective shelf registration statement on Form S-3 (File No. 333-266071) (the "U.S. Registration Statement"), including a base prospectus, previously filed with the Securities and Exchange Commission (the "SEC"). The Offering in the United States will be made only by means of a prospectus and related prospectus supplement meeting the requirements of Section 10 of the Securities Act of 1933, as amended. You may obtain these documents for free by visiting EDGAR on the SEC's website at Alternatively, copies of the U.S. Registration Statement, preliminary prospectus supplement and base prospectus may be obtained from National Bank of Canada Financial Markets, 130 King Street West, 4th Floor Podium, Toronto, Ontario M5X 1J9, by email at NBF-Syndication@ or by telephone at (416) 869-8414. The Offering may also be conducted in Canada and in offshore jurisdictions on a private placement basis in accordance with applicable securities laws. The Company intends to rely on the exemption in section 602.1 of the TSX Company Manual in respect of the Offering and the Private Placement as an eligible interlisted issuer. The Private Placement is expected to close concurrently with the closing of the Offering and is subject to customary conditions, including the completion of the Offering, but the Offering is not contingent upon the consummation of the Private Placement. The sale of the Common Shares under the Private Placement will not be registered under the Securities Act of 1933, as amended. Since neither the fair market value of the Common Shares to be acquired by the Paulson (an insider of the Company), nor the consideration for the Common Shares paid by Paulson, exceeds 25% of the Company's market capitalization as calculated in accordance with MI 61-101 (as defined below), the Private Placement is exempt from the formal valuation and minority approval requirements of Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101") pursuant to subsections 5.5(a) and 5.7(1)(a) of MI 61-101. No securities regulatory authority has either approved or disapproved the contents of this news release. This news release does not constitute an offer to sell or the solicitation of an offer to buy Common Shares, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. About Perpetua Resources and the Stibnite Gold ProjectPerpetua Resources Corp., through its wholly owned subsidiaries, is focused on the exploration, site restoration and redevelopment of gold-antimony-silver deposits in the Stibnite-Yellow Pine district of central Idaho that are encompassed by the Stibnite Gold Project. The Stibnite Gold Project is one of the highest-grade, open pit gold deposits in the United States and is designed to apply a modern, responsible mining approach to restore an abandoned mine site and produce both gold and the only mined source of antimony in the United States. Perpetua Resources has been awarded a Technology Investment Agreement of US$59.2 million in Defense Production Act Title III funding to advance construction readiness and permitting of the Stibnite Gold Project. Antimony trisulfide from Stibnite is the only known domestic reserves of antimony that can meet U.S. defense needs for many small arms, munitions, and missile types. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS OR INFORMATION Investors should be aware that the EXIM Letter of Interest ("LOI") is non-binding and conditional, and does not represent a financing commitment. A funding commitment, if any, is conditional upon successfully completing the due diligence and underwriting process, which may not be completed on the expected timeline, or at all. If the Company's application is approved, there can be no assurance that the EXIM financing will be for the full amount indicated in the LOI or the increased amount requested in the application, or that the approved EXIM financing will be sufficient for the Company to commence construction of the Project. Further, release of funding under any such commitment would be subject to the satisfaction of certain conditions and covenants by the Company. Statements contained in this news release that are not historical facts are "forward-looking information" or "forward-looking statements" (collectively, "Forward-Looking Information") within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward-Looking Information includes, but is not limited to, disclosure regarding the conduct of the Offering and Private Placement; the granting of the Underwriters' over-allotment option; the anticipated use of proceeds from the Offering and Private Placement; the occurrence of the expected benefits from the anticipated use of proceeds from the Offering, Private Placement, EXIM financing and royalty financing disclosure regarding the review process, anticipated timing and potential outcome of the Company's EXIM financing application; the amount of potential debt financing available to the Company; the eligibility of the Project for funding under the MMIA and CTEP initiatives; our ability to fully fund the construction of the Project and related financial assurance obligations; our ability to successfully implement and fund the Project; and the occurrence of the expected benefits from the Project, including providing a domestic source of antimony, national defense benefits, creation of jobs and environmental benefits. In certain cases, Forward-Looking Information can be identified by the use of words and phrases or variations of such words and phrases or statements such as "anticipate", "expect", "plan", "likely", "believe", "intend", "forecast", "project", "estimate", "potential", "could", "may", "will", "would" or "should". In preparing the Forward-Looking Information in this news release, Perpetua Resources has applied several material assumptions, including, but not limited to, assumptions that the EXIM application will be reviewed and approved within the expected timeframe at the amount equal to or higher than the amount indicated in the LOI; that the Company will be able to satisfy the conditions to obtain a funding commitment from EXIM and to receive committed funds when needed; general business and economic conditions will not change in a materially adverse manner and that permitting and operations costs will not materially increase; and that we will be able to discharge our liabilities as they become due and continue as a going concern. Forward-Looking Information are based on certain material assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Perpetua Resources to be materially different from any future results, performance or achievements expressed or implied by the Forward-Looking Information. Such risks and other factors include, among other things, risks related to delays in the EXIM application review process; any approved amount of EXIM financing may not be sufficient to commence construction of the Project; risks related to unforeseen delays in the review and permitting process, including as a result of legal challenges to the ROD or other permits; risks related to opposition to the Project; risks related to increased or unexpected costs in operations or the permitting process; risks that necessary financing will be unavailable when needed on acceptable terms, or at all, as well as those factors discussed in Perpetua Resources' public filings with the SEC and its Canadian disclosure record. Although Perpetua Resources has attempted to identify important factors that could affect Perpetua Resources and may cause actual actions, events or results to differ materially from those described in Forward-Looking Information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on Forward-Looking Information. For further information on these and other risks and uncertainties that may affect the Company's business and liquidity, see the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's filings with the SEC, which are available at and with the Canadian securities regulators, which are available at Except as required by law, Perpetua Resources does not assume any obligation to release publicly any revisions to Forward-Looking Information contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. View original content: SOURCE Perpetua Resources Corp. View original content:
New York Post
11 minutes ago
- New York Post
Dow falls 200 points after Trump threatens unilateral tariffs
Stocks fell at the open Thursday as investors reacted to renewed trade tensions after President Donald Trump threatened to impose unilateral tariffs on key U.S. trading partners. The Dow Jones Industrial Average dropped 230 points, or 0.54%, to 42,634.95 after the bell. The S&P 500 slid 0.28%, while the Nasdaq dipped 0.24%. The small-cap Russell 2000 also declined, losing 0.38%. 3 President Donald Trump said he plans to unilaterally impose tariffs on dozens of trading partners, reviving concerns about a global trade war and sending a jolt through financial markets. Shutterstock Meanwhile, the CBOE Volatility Index (VIX), Wall Street's 'fear gauge,' spiked more than 5%, signaling rising investor unease. The market downturn came hours after Trump, speaking Wednesday evening at the John F. Kennedy Center for the Performing Arts in Washington, confirmed that his administration intends to send letters to US trade partners in the coming weeks to formally establish new tariff terms. 'We're going to be sending letters out in about a week and a half, two weeks, to countries, telling them what the deal is,' Trump said. 'At a certain point, we're just going to send letters out. And I think you understand that, saying this is the deal, you can take it or leave it.' Trump's remarks come ahead of a July 9 deadline, when the White House is expected to move forward with increased tariffs on a wide range of imports unless new trade agreements are secured. 3 Dow Jones Industrial Average futures were down 302 points, or 0.70%, at 42,606.00 before the opening bell on Thursday. The S&P 500 futures slipped 37.25 points, or 0.62%. AP The president has previously floated similar timeframes, sometimes delaying or altering plans, but Thursday's selloff suggests investors are bracing for concrete action. In April, Trump proposed across-the-board tariff hikes but put them on hold for 90 days following a steep market decline. Since then, the administration has finalized only a narrow trade framework with the United Kingdom and a temporary tariff truce with China. That truce is now under pressure. Officials from Washington and Beijing met in London earlier this week for high-stakes negotiations after each side accused the other of breaching terms. Trump said Thursday that the US–China framework would include rare earth and magnet exports from China, in exchange for the US loosening restrictions on Chinese student visas. 3 In April, Trump proposed across-the-board tariff hikes but put them on hold for 90 days following a steep market decline. JOHN G MABANGLO/EPA-EFE/Shutterstock When asked whether he might extend the July 9 deadline to allow more time for deals, Trump said, 'But I don't think we're gonna have that necessity.' Trump has shifted his strategy away from blanket multilateral negotiations and is now focused on bilateral deals with countries such as India, Japan, South Korea and members of the European Union. Still, Commerce Secretary Howard Lutnick noted Thursday that negotiations with the EU have been difficult, pointing to the complexity of dealing with a 27-nation bloc. 'It's frustrating,' he said. With Trump reaffirming his tariff plans and few trade deals finalized, Thursday's sharp losses suggest markets are now pricing in the real possibility of a broader economic confrontation in the weeks ahead. The Post has sought comment from the White House.
Yahoo
15 minutes ago
- Yahoo
Black Buffalo Strengthens Leadership with Kit Dietz's Board Re-Election and Viv Penninti's Appointment as Senior Advisor
CHICAGO, June 12, 2025 /PRNewswire/ -- Black Buffalo Inc., the leading alternative to traditional smokeless tobacco, proudly announces the re-election of Kit Dietz to its Board of Directors and the appointment of Viv Penninti as Senior Advisor. Dietz has been elected to serve another term as Independent Director of Black Buffalo, after first joining the Board in March 2023. A seasoned executive and strategist, Dietz brings over four decades of experience in the nicotine and tobacco category. Notably, he served as an Independent Director on Lorillard's Board upon going public in 2008, through its $27 billion acquisition by Reynolds American in 2015, one of the most significant M&A transactions in industry history. Prior to his service at Lorillard, Dietz served as Chairman of Tripifoods Inc., a full-line convenience distributor in Buffalo, NY, and President of Michigan-based Spartan Stores Inc. Convenience Division. Penninti joined Black Buffalo effective January 2025 in a newly established role as Senior Advisor where he will guide Black Buffalo's data-driven sales and marketing strategies. Widely recognized as one of the key architects of data and analytics in the tobacco and nicotine industry for 30+ years, Penninti was the former CEO of Management Science Associates Inc. (MSAi), and subsequently the CEO of iGATE Global Solutions, a NASDAQ-listed IT company (that was later purchased by Cap Gemini). Penninti is currently the CEO of InRhythm, Inc. which is engaged in the development of an AI-driven business intelligence application. "Having Kit and Viv closely advising Black Buffalo in their respective capacities is an amazing benefit for our company, as well as our retail partners and wholesale customers," said Matthew Hanson, Chief Growth Officer at Black Buffalo, "Together, Kit and Viv have created some of the most widely used strategies and technologies in sales, data, and analytics in the industry, and we are honored that they have chosen to partner with Black Buffalo." As Black Buffalo continues to scale its retail presence and build toward long-term category leadership, the expertise of both Dietz and Penninti is critical to support Black Buffalo's strategic planning, retail acceleration, and performance optimization. About Black Buffalo Founded in 2015, Black Buffalo has created America's leading smokeless tobacco alternative products, backed by over 25,000 hours of research and development. The Company is a 3-time recipient of the Inc. 5000 Fastest-Growing Private Companies in America award (most recently in 2024), and Black Buffalo has won major Best New Product awards from the convenience trade. Black Buffalo smokeless tobacco alternative products are sold in-store and online. To learn more about Black Buffalo, visit the Company's website or use the Company's store locator to find Black Buffalo products at a local retailer near you. Interested retailers may contact wholesale@ to learn more about Black Buffalo. Certain Black Buffalo smokeless tobacco alternative products contain pharmaceutical-grade, tobacco-derived nicotine, which is an addictive chemical, and all of Black Buffalo's products are intended for adults aged 21 and older who are consumers of nicotine or tobacco. Black Buffalo's Forward-Looking Statements Any projections or other estimates herein are forward-looking statements and are based upon certain assumptions that Black Buffalo Inc. ("Black Buffalo," the "Company," "we," "us," "our," "ours," et. al as noted in context herein) has deemed reasonable. Financial, market, economic or legal conditions, the performance of the Company, regulatory developments, and other factors could cause actual results to differ materially from those set forth in the forward-looking statements herein. The business and prospects of the Company may have changed materially since the date hereof. Some of the factors that could cause actual results to differ materially from the forward-looking statements contained herein include, without limitation: (i) the contraction or lack of growth of markets in which we compete and in which our products are sold, (ii) unexpected increases in our expenses, including manufacturing expenses, (iii) delays or cancellations in spending by our suppliers or customers, (iv) delayed action on or issuance of marketing denied orders in response to our Premarket Tobacco Product Applications, or other negative actions taken by, the U.S. Food and Drug Administration, and (v) the impact of pandemics or natural disasters on our sourcing operations and supply chain. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. Black Buffalo Media ContactsJeffery David (JD), Co-Founder + Chief Brand Officerjd@ Hanson, Chief Growth Officermatthew@ View original content to download multimedia: SOURCE Black Buffalo Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
